Benign prostatic hyperplasia: Natural evolution versus medical treatment

被引:0
|
作者
DaSilva, FC
机构
关键词
benign prostatic hyperplasia; alpha(1)-blockers; quality of life; epidemiology;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The epidemiology and natural evolution of benign prostatic hyperplasia (BPH) are important when considering the topic of natural evolution versus medical treatment, The incidence of BPH increases with age; it is thought that about 75 % of men over 50 years of age suffer from some symptoms commonly associated with BPH. There are also differences in the incidence of BPH between various racial and ethnic groups. For example, it is considerably less common amongst Japanese men compared with Caucasians. Evidence from prospective studies, retrospective studies and the placebo arms of randomised, controlled studies regarding the natural evolution of BPH suggests that a strategy of 'watchful waiting' may be considered as a treatment option as the majority of patients do not show a worsening of symptoms over time, However, the chance for improvement of symptoms and the degree of symptom improvement has been shown to be higher with alpha(1)-blocker therapy than with 'watchful waiting', as both symptoms and treatment have an impact on the patient's quality of life, there is now a strong case for involving the patient in making quality-of-life decisions based on his own preferences and attitudes.
引用
收藏
页码:34 / 37
页数:4
相关论文
共 50 条
  • [41] Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia
    Roehrborn, Claus G.
    Rukstalis, Daniel B.
    EUROPEAN UROLOGY FOCUS, 2022, 8 (01): : 217 - 227
  • [42] Medical management of patients with benign prostatic hyperplasia: A study in Indian population
    Shah, Amit Kumar
    Srivastava, Anand
    Karan, S. C.
    JOURNAL OF MARINE MEDICAL SOCIETY, 2018, 20 (02) : 104 - 110
  • [43] Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments
    Welliver, Charles
    Essa, Ahmed
    UROLOGIC CLINICS OF NORTH AMERICA, 2016, 43 (03) : 393 - +
  • [44] A comprehensive review of medical therapy on benign prostatic hyperplasia
    Sugianto, R.
    Tirtayasa, P. M. W.
    Duarsa, G. W. K.
    SEXOLOGIES, 2022, 31 (01) : 52 - 60
  • [45] Treatment of benign prostatic hyperplasia: Update and future
    Chiu, Tai-Hua
    Wu, Yi-Hsuan
    Lee, Yung-Chin
    UROLOGICAL SCIENCE, 2023, 34 (02) : 55 - 63
  • [47] Medical therapy for benign prostatic hyperplasia: A review of the literature
    Clifford, GM
    Farmer, RDT
    EUROPEAN UROLOGY, 2000, 38 (01) : 2 - 19
  • [48] Emerging drugs for the treatment of benign prostatic hyperplasia
    Thomas, Dominique
    Chughtai, Bilal
    Kini, Mitali
    Te, Alexis
    EXPERT OPINION ON EMERGING DRUGS, 2017, 22 (03) : 201 - 212
  • [49] Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia
    Lee, M
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (14) : 1426 - 1439
  • [50] Benign prostatic hyperplasia, from pathophysiology to treatment
    Coudert, Pascal
    ACTUALITES PHARMACEUTIQUES, 2024, 63 (640): : 28 - 32